

Electronic Supplemental material 1

Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands

Drug Safety – Original Research

Author information

Agnes Kant¹, Jurriaan Jansen¹, Leontine van Balveren¹, Florence van Hunsel¹

Affiliations

¹ Netherlands Pharmacovigilance Centre Lareb, 's Hertogenbosch, the Netherlands.

Correspondence: f.vanhunsel@lareb.nl

Table 1. Data on vaccines given in the Netherlands until 07-10-2021, stratified per age, sex and dose [1].

Age	Gender	AstraZeneca 1st dose	AstraZeneca 2nd dose	Pfizer 1st dose	Pfizer 2nd dose	Moderna 1st dose	Moderna 2nd dose	Janssen 1st dose	Unknown brand 1st dose	Unknown brand 2nd dose
10-19	Female	3328	3164	451676	360037	12787	10768	16095	12	0
20-29	Female	34717	32686	561687	470182	81756	72362	82039	29	6
30-39	Female	35095	32743	625176	547609	86964	79220	39795	35	4
40-49	Female	48377	45339	645926	580289	129740	119499	52887	31	5
50-59	Female	79861	75104	767458	708810	145776	135618	117116	38	3
60-69	Female	452144	429602	510542	485788	26245	24399	5123	11	3
70-79	Female	10374	9351	784187	763707	13197	12257	1044	6	3
80-89	Female	8112	6993	388593	379603	7275	6407	317	7	3
90-99	Female	5841	4933	84673	80895	5690	5023	38	2	2
100-109	Female	245	204	2002	1810	293	244	3	0	0
110-119	Female	0	0	1	1	1	1	0	0	0
unknown	Female	5	4	1018	779	95	68	21	0	0

10-19	Male	1297	1194	464639	373564	12590	10444	24807	18	0
20-29	Male	12391	11665	556133	454684	74342	64104	137463	118	75
30-39	Male	14121	13403	650595	575441	79572	72588	54244	86	35
40-49	Male	18293	17434	647510	584143	126852	117747	61479	45	14
50-59	Male	29988	28566	790291	726561	157487	146801	142518	52	15
60-69	Male	498079	473302	457450	432458	29431	27528	5539	14	3
70-79	Male	11356	10303	734772	715116	15513	14628	1434	12	5
80-89	Male	5060	4290	292274	285953	3360	2988	327	7	3
90-99	Male	2355	1981	38244	36646	1597	1401	32	0	0
100-109	Male	55	45	434	404	57	50	0	0	0
110-119	Male	0	0	1	1	0	0	0	0	0
unknown	Male	8	7	1211	931	136	91	59	0	0
10-19	Unknown	3	3	1422	1017	8	7	87	0	0
20-29	Unknown	32	32	1079	706	48	45	595	2	0
30-39	Unknown	35	34	1195	893	76	67	679	1	0
40-49	Unknown	48	46	1496	1285	166	155	591	3	0
50-59	Unknown	94	93	2540	2385	346	333	727	0	0
60-69	Unknown	63	56	1549	1457	46	42	114	3	0
70-79	Unknown	1	0	4064	3963	13	12	29	1	0
80-89	Unknown	1	1	1392	1357	3	3	8	0	0
90-99	Unknown	0	0	176	175	0	0	1	0	0
100-109	Unknown	0	0	2	1	0	0	0	0	0
110-119	Unknown	0	0	0	0	0	0	0	0	0
unknown	Unknown	30	16	411	223	33	13	36	4	0

- The Municipal Public Health Service (GGD) or a vaccinated person's General Practitioner will only share a person's data with RIVM if this person gives consent for it to be shared. We have data from CIMS, separately for age and sex.
- Numbers for AstraZeneca may not be entirely complete due to a lag in registration

[1] The National Institute for Public Health and the Environment (RIVM). The COVID-19 vaccination Information and Monitoring System (CIMS). Data provided by the RIVM.